Topics

Sotatercept for PAH gains Orphan Drug status

06:02 EDT 12 Sep 2019 | SmartBrief

Acceleron Pharma's sotatercept, indicated as a treatment for pulmonary arterial hypertension, gained Orphan Drug designation  -More

Original Article: Sotatercept for PAH gains Orphan Drug status

NEXT ARTICLE

More From BioPortfolio on "Sotatercept for PAH gains Orphan Drug status"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...